Details

Autor(en) / Beteiligte

• Rao, Madhumathi
• Guo, Daqing
• Jaber, Bertrand L.
• Tighiouart, Hocine
• Pereira, Brian J.G.
• Balakrishnan, Vaidyanathapuram S.

Titel

Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients

Ist Teil von

• Kidney international, 2004-07, Vol.66 (1), p.419-427

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2004

Quelle

Elektronische Zeitschriftenbibliothek

Beschreibungen/Notizen

• Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Atherosclerotic vascular disease is a leading cause of morbidity and mortality in patients with end-stage renal disease (ESRD) on maintenance hemodialysis (HD). Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine that inhibits the atheromatous process. We studied coding region polymorphisms of the TGF-β1 gene (+869 T → C at codon 10 and +915 G → C at codon 25) as genetic susceptibility factors for prevalent vascular disease and cardiac outcomes in a cohort of HD patients enrolled in the HEMO Study. Genotyping was carried out using polymerase chain reaction-sequence specific primer (PCR-SSP) methods with a cytokine genotyping tray. Prevalent vascular disease was coded from the Index of Disease Severity (IDS) scores for ischemic heart disease (IHD), peripheral vascular disease (PVD), cerebrovascular disease (CVD), and congestive heart failure (CHF), 0 indicating absence, and 1 to 3 increasing grades of severity. The presence of any vascular disease (VD) (i.e., any degree of IHD/PVD/CVD), and the number of coexistent vascular system diseases per patient were derived. Cardiac outcomes, one of the secondary outcomes of the HEMO Study, were expressed as a composite of the first hospitalization for, or death from, cardiac causes. The cohort consisted of 183 patients at enrollment, 56% male, 44% African American (AA), and 40% diabetic. The mean age was 62.4 ± 12.2 years, and median dialysis vintage 2.02 years. The most frequent genotype at codon 10 was T/C (67%), and at codon 25 was G/G (72%). IHD was present in 52% of patients; 65% had at least one vascular system involvement, and 31% had 2 or more. On both univariate and multivariate analysis, the G/C genotype at codon 25 was significantly associated with the presence and extent of vascular disease at enrollment. The median time to cardiac outcome, defined as a composite of the first hospitalization for, or death from, cardiac causes, was 411 days in patients with the G/C genotype compared with 851 days in those with the G/G genotype (P = 0.03). Patients with the G/C genotype had a 1.6-fold increased hazard for cardiac outcomes after adjustment for baseline covariates (P = 0.04). The G/C substitution at codon 25 was associated with an increased risk for prevalent vascular disease, new onset cardiac morbidity, and cardiac mortality in HD patients, and may be a genetic susceptibility factor for the development of atherosclerosis. Further studies are required to evaluate the role of TGF-β1 as a candidate gene.